ctDNA for MRD assessment is prognostic and predictive in newly…
Blood tests detecting cancer DNA after treatment predict survival better than imaging, potentially enabling earlier intervention in lymphoma patients.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Induction TPF versus adjuvant PF after CCRT in locally advanced…
Adding chemotherapy before standard treatment didn't improve survival for advanced nasopharyngeal cancer but did reduce quality-of-life side effects like difficulty swallowing.
Promising but preliminaryEmerging therapeutic opportunities targeting nonclassical MHC-I molecules.
Newly recognized immune molecules offer fresh targets for off-the-shelf cell therapies, potentially making personalized cancer treatments more accessible and affordable.
Promising but preliminaryProximity-confined DNA walking-nanozyme cascades for multiplexed…
A urine test using engineered particles can detect cancer signatures with high accuracy, suggesting a noninvasive screening approach for prostate cancer.
Promising but preliminaryAtezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan
One immunotherapy drug worked as well as another for advanced lung cancer but cost less, caused fewer side effects, and reduced severe lung inflammation in Japanese patients.